替奈普酶在缺血性卒中中提供更好的血管再通:两项试验分析
该研究汇总两项2期随机试验的临床和影像数据,比较替奈普酶与阿替普酶在完全血管闭塞患者中的再通和临床结局。结果显示,替奈普酶组24小时完全再通率更高(71% vs 43%,p<0.001),早期临床改善更明显,90天良好结局率更高(OR 4.82,95%CI 1.02-7.84,p=0.05)。
要点
- 替奈普酶较阿替普酶显著提高完全闭塞患者24小时完全再通率。
- 替奈普酶组24小时NIHSS改善中位数更大,90天良好结局率更高。
- 基线CTA完全闭塞患者可能从替奈普酶治疗中获益更明显。
核心结论
- 替奈普酶可能比阿替普酶具有更好的再通疗效,在基线CTA完全血管闭塞患者中可能更明显。
研究设计与样本
- 汇总两项比较替奈普酶与阿替普酶的2期随机试验的临床和影像数据,共146例患者,由中心评估基线及溶栓后24小时CTA的闭塞状态(改良TICI量表)。
主要发现
- 146例 pooled 患者中69例基线存在TICI 0/1闭塞。
- 替奈普酶治疗完全血管闭塞患者24小时完全再通率为71%,阿替普酶为43%(p<0.001)。
- TICI 0/1闭塞患者中,替奈普酶组24小时NIHSS变化中位数为9(IQR 6),阿替普酶组为1(IQR 1),p=0.001。
- 替奈普酶组90天良好结局(mRS 0-1)优于阿替普酶组,OR 4.82(95%CI 1.02-7.84),p=0.05。
临床怎么用
- 对于基线CTA显示完全血管闭塞的缺血性卒中患者,替奈普酶可能提供更高的再通率和更好的早期及90天临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test whether patients with complete vessel occlusion show greater recanalization at 24 hours and have improved clinical outcomes at 24 hours and 90 days when treated with tenecteplase compared to alteplase. METHODS: Pooled clinical and imaging data from 2 phase 2 randomized trials comparing tenecteplase with alteplase allowed CT angiography (CTA) scans to be assessed centrally for occlusion status at baseline and at 24 hours post thrombolysis using the modified thrombolysis in cerebral infarction (TICI) scale. Twenty-four-hour poststroke NIH Stroke Scale (NIHSS) and 90-day modified Rankin Scale (mRS) scores were also compared between treatment groups using linear regression to generate odds ratios (ORs). RESULTS: From 146 pooled patients, 69 had a TICI 0/1 occlusion overall at baseline. Tenecteplase-treated patients with a complete vessel occlusion had greater complete recanalization rates at 24 hours (71% for tenecteplase vs 43% for alteplase, p < 0.001). Patients with a TICI 0/1 occlusion who were treated with tenecteplase also showed greater early clinical improvement (median NIHSS change with tenecteplase was 9, interquartile range [IQR] 6, alteplase 1, IQR 1, p = 0.001) and higher rates of favorable 90-day outcomes (mRS 0-1 of tenecteplase compared with alteplase, OR 4.82, 95% confidence interval 1.02-7.84, p = 0.05). CONCLUSIONS: Tenecteplase may offer greater recanalization efficacy compared to alteplase, possibly exaggerated in patients with complete vessel occlusions on baseline CTA.
引用
- Bivard A, Huang X, Levi CR, et al. Tenecteplase in ischemic stroke offers improved recanalization: Analysis of 2 trials. Neurology. 2017. PMID: 28576782. doi:10.1212/WNL.0000000000004062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。